Shared Decision Making With Breast Cancer Patients

NCT ID: NCT04177628

Last Updated: 2023-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

678 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-04

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this project is to elucidate whether the use of shared decision making will influence patient engagement in the decision making process about adjuvant radiotherapy after breast conserving surgery for local breast cancer or early stages of local breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The risk of recurrence of breast cancer is lowered by adjuvant medical treatment as well as by radiotherapy (RT). On the other hand, all adjuvant treatments involve a risk of side effects; some are acute and transient while others are long-term. Considering the well-known side effects of irradiation, it seems appropriate to involve patients in the decision on whether to receive irradiation.

In the shared decision making (SDM) process clinicians and patients work together to make appropriate health decisions based on clinical evidence and the patient's informed preferences. A patient decision aid (PtDA) is instrumental in the SDM process.

This study is a multicenter, national trial randomizing doctors to either use or not use SDM and a PtDA when informing the patients about benefits and risks of receiving adjuvant radiotherapy.

It is not expected that significantly less patients will receive radiotherapy as a consequence of SDM. The primary aim of the study is to evaluate whether patient engagement in decision making is affected by SDM and the use of an in-consultation PtDA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Shared Decision Making Breast Neoplasms Radiotherapy, Adjuvant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Half the doctors at each center will receive training in SDM. These doctors will practice SDM supported by the in-consultation PtDA during every consultation in this study. The other half of the doctors will continue usual practice of informing the patients.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: Shared decision making

Patients will be informed by a doctor randomized to practice shared decision making and use the in-consultation PtDA during the consultation on adjuvant radiotherapy.

Group Type EXPERIMENTAL

Shared decision making supported by an in-consultation patient decision aid

Intervention Type BEHAVIORAL

After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.

Arm B: Usual practice

Patients will be informed by a doctor randomized to inform about adjuvant radiotherapy according to usual practice.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Shared decision making supported by an in-consultation patient decision aid

After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically verified breast cancer or ductal carcinoma in situ breast cancer
* Candidate for adjuvant radiotherapy Danish Breast Cancer Group type F after breast-conserving surgery for T1-2, N0-Nmi, M0 disease according to national guidelines.
* Signed confirmation of participation.

Exclusion Criteria

* Bilateral breast cancer or suspicion of disseminated cancer
* Unable to understand the information, the planned treatment or follow-up for any reason.
* Earlier radiotherapy towards the thoracic region.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Danish Breast Cancer Cooperative Group

OTHER

Sponsor Role collaborator

University of Southern Denmark

OTHER

Sponsor Role collaborator

Danish Comprehensive Cancer Center

OTHER

Sponsor Role collaborator

Vejle Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karina D Steffensen, Professor

Role: STUDY_CHAIR

Vejle Hospital

Stine R Sondergaard, M.D.

Role: PRINCIPAL_INVESTIGATOR

Vejle Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aalborg Hospital

Aalborg, , Denmark

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

Herlev University Hospital

Herlev, , Denmark

Site Status

Sjaellands University Hospital

Næstved, , Denmark

Site Status

Odense University Hospital

Odense, , Denmark

Site Status

Vejle Hospital

Vejle, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DBCG RT SDM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rehabilitation After Breast Cancer
NCT03254875 COMPLETED NA